Universal Beteiligungs und Servicegesellschaft mbH Buys 70,320 Shares of Bristol Myers Squibb Company $BMY

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 4.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,742,579 shares of the biopharmaceutical company’s stock after acquiring an additional 70,320 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of Bristol Myers Squibb worth $78,590,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at approximately $1,554,154,000. Charles Schwab Investment Management Inc. grew its stake in shares of Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Bristol Myers Squibb by 428.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after purchasing an additional 9,171,098 shares during the period. Man Group plc boosted its stake in shares of Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Bristol Myers Squibb by 142.8% during the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after buying an additional 4,961,869 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Partnership with Microsoft to pilot AI radiology for earlier lung‑cancer detection — strengthens BMY’s diagnostics and R&D capabilities, raises potential long‑term clinical and commercial benefits. Article Title
• Positive Sentiment: UBS upgraded BMY to Buy, noting an attractive risk/reward — an upward analyst stance that can support buying interest and higher valuation expectations. Article Title
• Positive Sentiment: Scotiabank and other outlets highlighted BMY as an appealing oncology/dividend pick and raised price targets — incremental analyst support that may buoy investor confidence. Article Title
• Neutral Sentiment: Industry coverage & stock lists (Zacks comparison with GSK; dividend‑stock ETFs and blue‑chip roundup pieces) keep BMY in investor screens but are broad‑market context rather than company‑specific catalysts. Article Title
• Negative Sentiment: Zacks issued mixed estimate moves: a tiny raise to Q4 2027 EPS (from $1.44 to $1.45) but cuts to Q1 2027 (1.36 → 1.33) and FY2027 (5.91 → 5.90). Those near‑term downgrades — even if small — can dampen sentiment and help explain intraday weakness as investors focus on near‑term earnings visibility.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $54.20 on Wednesday. The firm has a market cap of $110.34 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The business’s 50 day moving average price is $52.18 and its two-hundred day moving average price is $48.24. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period last year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BMY. HSBC reaffirmed a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company raised their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Finally, Leerink Partners upped their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Seven investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.